Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy

Amanda Mocroft; Andrew N Phillips; Bruno Ledergerber; Colette Smith; Johannes R Bogner; Karine Lacombe; Alicje Wiercinska-Drapalo; Peter Reiss; Ole Kirk; Jens Lundgren; Eurosida Study Group

doi:10.3851/IMP1559

Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy

Amanda Mocroft, Andrew N Phillips, Bruno Ledergerber, Colette Smith, Johannes R Bogner, Karine Lacombe, Alicje Wiercinska-Drapalo, Peter Reiss, Ole Kirk, Jens Lundgren, Eurosida Study Group

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

13 Citationer (Scopus)

Abstract

Udgivelsesdato: 2010-null

Originalsprog	Engelsk
Tidsskrift	Antiviral Therapy
Vol/bind	15
Udgave nummer	4
Sider (fra-til)	563-70
Antal sider	8
ISSN	1359-6535
DOI	https://doi.org/10.3851/IMP1559 https://doi.org/10.3851/IMP1559
Status	Udgivet - 1 jan. 2010

Adgang til dokumentet

Citationsformater

Mocroft, A., Phillips, A. N., Ledergerber, B., Smith, C., Bogner, J. R., Lacombe, K., Wiercinska-Drapalo, A., Reiss, P., Kirk, O., Lundgren, J., & Eurosida Study Group (2010). Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy. Antiviral Therapy, 15(4), 563-70. https://doi.org/10.3851/IMP1559, https://doi.org/10.3851/IMP1559

Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy. / Mocroft, Amanda; Phillips, Andrew N; Ledergerber, Bruno; Smith, Colette; Bogner, Johannes R; Lacombe, Karine; Wiercinska-Drapalo, Alicje; Reiss, Peter; Kirk, Ole ; Lundgren, Jens; Eurosida Study Group.

I: Antiviral Therapy, Bind 15, Nr. 4, 01.01.2010, s. 563-70.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Mocroft, A, Phillips, AN, Ledergerber, B, Smith, C, Bogner, JR, Lacombe, K, Wiercinska-Drapalo, A, Reiss, P, Kirk, O , Lundgren, J & Eurosida Study Group 2010, 'Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy', Antiviral Therapy, bind 15, nr. 4, s. 563-70. https://doi.org/10.3851/IMP1559, https://doi.org/10.3851/IMP1559

Mocroft, Amanda ; Phillips, Andrew N ; Ledergerber, Bruno ; Smith, Colette ; Bogner, Johannes R ; Lacombe, Karine ; Wiercinska-Drapalo, Alicje ; Reiss, Peter ; Kirk, Ole ; Lundgren, Jens ; Eurosida Study Group. / Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy. I: Antiviral Therapy. 2010 ; Bind 15, Nr. 4. s. 563-70.

@article{0e263de084f711df928f000ea68e967b,

title = "Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy",

abstract = "BACKGROUND: Patients receiving combination antiretroviral therapy (cART) might continue treatment with a virologically failing regimen. We sought to identify annual change in CD4(+) T-cell count according to levels of viraemia in patients on cART. METHODS: A total of 111,371 CD4(+) T-cell counts and viral load measurements in 8,227 patients were analysed. Annual change in CD4(+) T-cell numbers was estimated using mixed models. RESULTS: After adjustment, the estimated average annual change in CD4(+) T-cell count significantly increased when viral load was <500 copies/ml (30.4 cells/mm(3), 95% confidence interval [CI] 26.6-34.3), was stable when viral load was 500-9,999 copies/ml (3.1 cells/mm(3), 95% CI -5.3-11.5) and decreased when viral load was >/=10,000 copies/ml (-14.8 cells/mm(3), 95% CI -4.5--25.1). Patients taking a boosted protease inhibitor (PI) regimen had more positive annual CD4(+) T-cell count changes than patients taking other regimens for any given viral load strata: 30.9 cells/mm(3) (95% CI 27.7-34.1) when viral load was <500 copies/ml, 14.2 cells/mm(3) (95% CI -2.1-30.4) when viral load was 500-9,999 copies/ml and -19.9 cells/mm(3) (95% CI -36.6--3.3) when viral load was >/=10,000 copies/ml. By contrast, among patients taking a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen, the CD4(+) T-cell count significantly decreased when the viral load was 500-9,999 copies/ml (-18.6 cells/mm(3), 95% CI -33.8--3.5) and decreased at a faster rate when the viral load was >/=10,000 copies/ml (-44.4 cells/mm(3), 95% CI -62.0--26.9; P=0.0012, test for interaction). CONCLUSIONS: On average, CD4(+) T-cell counts did not significantly decrease until the viral load exceeded 10,000 copies/ml in patients treated with a boosted PI-containing cART regimen, but decreased in patients taking an NNRTI-based cART regimen when viral load was 500-9,999 copies/ml.",

author = "Amanda Mocroft and Phillips, {Andrew N} and Bruno Ledergerber and Colette Smith and Bogner, {Johannes R} and Karine Lacombe and Alicje Wiercinska-Drapalo and Peter Reiss and Ole Kirk and Jens Lundgren and Ole Kirk",

year = "2010",

month = jan,

day = "1",

doi = "10.3851/IMP1559",

language = "English",

volume = "15",

pages = "563--70",

journal = "Antiviral Therapy",

issn = "1359-6535",

publisher = "International Medical Press",

number = "4",

}

TY - JOUR

T1 - Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy

AU - Mocroft, Amanda

AU - Phillips, Andrew N

AU - Ledergerber, Bruno

AU - Smith, Colette

AU - Bogner, Johannes R

AU - Lacombe, Karine

AU - Wiercinska-Drapalo, Alicje

AU - Reiss, Peter

AU - Kirk, Ole

AU - Lundgren, Jens

AU - Eurosida Study Group

PY - 2010/1/1

Y1 - 2010/1/1

N2 - BACKGROUND: Patients receiving combination antiretroviral therapy (cART) might continue treatment with a virologically failing regimen. We sought to identify annual change in CD4(+) T-cell count according to levels of viraemia in patients on cART. METHODS: A total of 111,371 CD4(+) T-cell counts and viral load measurements in 8,227 patients were analysed. Annual change in CD4(+) T-cell numbers was estimated using mixed models. RESULTS: After adjustment, the estimated average annual change in CD4(+) T-cell count significantly increased when viral load was <500 copies/ml (30.4 cells/mm(3), 95% confidence interval [CI] 26.6-34.3), was stable when viral load was 500-9,999 copies/ml (3.1 cells/mm(3), 95% CI -5.3-11.5) and decreased when viral load was >/=10,000 copies/ml (-14.8 cells/mm(3), 95% CI -4.5--25.1). Patients taking a boosted protease inhibitor (PI) regimen had more positive annual CD4(+) T-cell count changes than patients taking other regimens for any given viral load strata: 30.9 cells/mm(3) (95% CI 27.7-34.1) when viral load was <500 copies/ml, 14.2 cells/mm(3) (95% CI -2.1-30.4) when viral load was 500-9,999 copies/ml and -19.9 cells/mm(3) (95% CI -36.6--3.3) when viral load was >/=10,000 copies/ml. By contrast, among patients taking a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen, the CD4(+) T-cell count significantly decreased when the viral load was 500-9,999 copies/ml (-18.6 cells/mm(3), 95% CI -33.8--3.5) and decreased at a faster rate when the viral load was >/=10,000 copies/ml (-44.4 cells/mm(3), 95% CI -62.0--26.9; P=0.0012, test for interaction). CONCLUSIONS: On average, CD4(+) T-cell counts did not significantly decrease until the viral load exceeded 10,000 copies/ml in patients treated with a boosted PI-containing cART regimen, but decreased in patients taking an NNRTI-based cART regimen when viral load was 500-9,999 copies/ml.

AB - BACKGROUND: Patients receiving combination antiretroviral therapy (cART) might continue treatment with a virologically failing regimen. We sought to identify annual change in CD4(+) T-cell count according to levels of viraemia in patients on cART. METHODS: A total of 111,371 CD4(+) T-cell counts and viral load measurements in 8,227 patients were analysed. Annual change in CD4(+) T-cell numbers was estimated using mixed models. RESULTS: After adjustment, the estimated average annual change in CD4(+) T-cell count significantly increased when viral load was <500 copies/ml (30.4 cells/mm(3), 95% confidence interval [CI] 26.6-34.3), was stable when viral load was 500-9,999 copies/ml (3.1 cells/mm(3), 95% CI -5.3-11.5) and decreased when viral load was >/=10,000 copies/ml (-14.8 cells/mm(3), 95% CI -4.5--25.1). Patients taking a boosted protease inhibitor (PI) regimen had more positive annual CD4(+) T-cell count changes than patients taking other regimens for any given viral load strata: 30.9 cells/mm(3) (95% CI 27.7-34.1) when viral load was <500 copies/ml, 14.2 cells/mm(3) (95% CI -2.1-30.4) when viral load was 500-9,999 copies/ml and -19.9 cells/mm(3) (95% CI -36.6--3.3) when viral load was >/=10,000 copies/ml. By contrast, among patients taking a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen, the CD4(+) T-cell count significantly decreased when the viral load was 500-9,999 copies/ml (-18.6 cells/mm(3), 95% CI -33.8--3.5) and decreased at a faster rate when the viral load was >/=10,000 copies/ml (-44.4 cells/mm(3), 95% CI -62.0--26.9; P=0.0012, test for interaction). CONCLUSIONS: On average, CD4(+) T-cell counts did not significantly decrease until the viral load exceeded 10,000 copies/ml in patients treated with a boosted PI-containing cART regimen, but decreased in patients taking an NNRTI-based cART regimen when viral load was 500-9,999 copies/ml.

U2 - 10.3851/IMP1559

DO - 10.3851/IMP1559

M3 - Journal article

C2 - 20587849

VL - 15

SP - 563

EP - 570

JO - Antiviral Therapy

JF - Antiviral Therapy

SN - 1359-6535

IS - 4

ER -